Citigroup
SANA icon

Citigroup’s Sana Biotechnology SANA Stock Holding History

Citigroup’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,700
Closed -$61.2K – 5937
2024
Q3 		$61.2K Sell
14,700
-200
-1% -$1.05K ﹤0.01% 4960
2024
Q2 		$81.4K Buy
+14,900
New +$119K ﹤0.01% 4320

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Citigroup's SANA Position: Q1 2026 in Review

Citigroup reduced its Sana Biotechnology (SANA) stake by 61% in Q1 2026, selling an estimated $372K and leaving 60,391 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #4061.

Citigroup first reported a position in SANA in Q1 2021 and has held it in 21 quarters since. The position peaked at $4.7M in Q1 2024. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Citigroup held 60,391 shares of Sana Biotechnology worth $174K as of Q1 2026.
  • Citigroup sold 94,373 Sana Biotechnology shares in Q1 2026, an estimated $372K.
  • Sana Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4061 holding.
  • Citigroup first reported a position in Sana Biotechnology in Q1 2021 and has held it in 21 quarters since.
  • Citigroup's Sana Biotechnology position peaked at $4.7M in Q1 2024.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.